Robert M Sutphin MD (He/Him)
Medical Director Hematology Oncology ICON Biotech / Therapeutic Expertise / Medical Affairs
Join to View Full Profile
92 W Miller StOrlando, FL 32806
Phone+1 321-230-8138
Fax+1 407-337-0137
Dr. Sutphin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Sutphin is a pediatric hematologist and oncologist located in Orlando, FL. He currently serves as Medical Director at ICON PLC supporting global clinical trials focused in oncology.
He completed his pediatrics residency at the University of Florida and a fellowship in pediatric hematology/oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2007
University of Florida (Orlando)Residency, Pediatrics, 2001 - 2004
Marshall University Joan C. Edwards School of MedicineClass of 2001
Certifications & Licensure
FL State Medical License 2007 - 2027
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients Start of enrollment: 2010 Jan 01
- Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Jul 18
Publications & Presentations
PubMed
- 1 citationsCombination Chemotherapy in Severe Pulmonary Vein Stenosis-A Case Series.Gabriel Krivenko, Karen Iacono, David Nykanen, Robyn Keen, Robert Sutphin
Children. 2023-02-11 - 5 citationsCombination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cellsShruti Patil, Umesh T. Sankpal, Myrna Hurtado, W. Paul Bowman, Jeffrey Murray
Gene. 2019-07-15 - 5 citationsCombination of 13 cis-retinoic acid and tolfenamic acid induces apoptosis and effectively inhibits high-risk neuroblastoma cell proliferation.Sagar Shelake, Don Eslin, Robert M. Sutphin, Umesh T Sankpal PhD, Anmol Wadwani
International Journal of Developmental Neuroscience. 2015-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
